中国临床药理学杂志2025，Vol.41Issue(2)：188-192,5.DOI:10.13699/j.cnki.1001-6821.2025.02.008
右美托咪定复合艾司氯胺酮用于口腔鳞状细胞癌根治术患者的临床研究
Clinical trial of dexmedetomidine combined with esketamine in the treatment of patients with oral squamous cell carcinoma radical resection
摘要
Abstract
Objective To observe the clinical efficacy and safety of dexmedetomidine injection combined with esketamine injection in the treatment of patients with oral squamous cell carcinoma radical resection.Methods Patients with oral squamous cell carcinoma radical resection were randomly divided into treatment and control groups.The treatment group will receive intravenous administration of 0.6 μg•kg-1 dexmedetomidine 10 minutes before anesthesia induction.Subsequently,anesthesia induction will be performed with intravenous administration of 0.5 mg•kg-1 esketamine.Anesthesia maintenance will be achieved with intravenous infusion of 0.25 mg•kg-1•h-1 esketamine and 0.3 μg•kg-1•h-1 dexmedetomidine used an infusion pump.The control group will receive intravenous administration of an equivalent volume of 0.9％NaCl 10 minutes before anesthesia induction.Anesthesia induction will then be performed with intravenous administration of 2.5-5.0 µg•kg-1 fentanyl.Anesthesia maintenance will involve intravenous infusion of 0.10-0.25 µg•kg-1•min-1 remifentanil used an infusion pump.The anesthesia effectiveness,analgesic effectiveness,hemodynamics and safety were compared between the two groups.Results Treatment group were enrolled 62 cases,1 case dropped out,and 61 cases were finally included in the statistical analysis.Control group were enrolled 61 cases,1 case dropped out,and 60 cases were finally included in the statistical analysis.The recovery room stay time of treatment and control groups was(25.97±4.52)and(18.39±3.64)min,the extubation time was(16.75±4.84)and(10.16±3.18)min,and the differences were statistically significant(all P＜0.05).After operation 24 h,visual analogue scores of treatment and control groups were(0.85±0.17)and(1.39±0.25)points,adrenocorticotropin levels were(60.07±7.13)and(72.64±9.81)pg•mL-1,cortisol levels were(481.20±49.15)and(539.94±57.77)nmol•L-1,and the differences were statistically significant(all P＜0.05).The mean arterial pressure at 30 min after anesthesia induction(T1)and at the end of surgery(T2)in treatment group were(82.34±4.98)and(86.57±4.18)mmHg,while those in control group were(77.25±7.16)and(76.02±6.29)mmHg;the heart rates of T1 and T2 in treatment groups were(64.08±4.19)and(66.45±4.83)time•min-1,while those in control group were(68.44±6.02)and(72.08±7.27)time•min-1;and the differences were statistically significant(all P＜0.05).The adverse drug reactions in two groups were nausea,vomiting,bradycardia and dizziness.The total incidences of adverse drug reactions in treatment and control groups were 8.20％and 15.00％,without significant difference(P＞0.05).Conclusion Dexmedetomidine injection combined with esketamine injection has a definitive analgesia efficacy in the treatment of patients with oral squamous cell carcinoma radical resection,which can significantly reduce stress responses,maintain hemodynamic stability,without increasing the incidence of adverse drug reactions.关键词
右美托咪定注射液/艾司氯胺酮注射液/口腔鳞状细胞癌/安全性评价Key words
dexmedetomidine injection/esketamine injection/oral squamous cell carcinoma/safety evaluation分类
医药卫生引用本文复制引用
陈建兴,林文谦,吴雅君,陈志建..右美托咪定复合艾司氯胺酮用于口腔鳞状细胞癌根治术患者的临床研究[J].中国临床药理学杂志,2025,41(2):188-192,5.基金项目
福建省自然科学基金资助项目(2022J011369) （2022J011369）
